BMJ12d
Vascular occlusion for optimising the functional improvement in patients with knee osteoarthritis: a randomised controlled trial
Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
BMJ3d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ12d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ11d
Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis
Correspondence to Dr Ki-Jo Kim, Division of Rheumatology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, ...
BMJ6d
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Objectives To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
BMJ12d
Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE
Objectives The goals of these studies were to elucidate the inter-relationships of specific anti-nuclear antibody (ANA), complement, and the interferon gene signature (IGS) in the pathogenesis of ...
BMJ8d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ11d
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Objective To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods Fifty-three patients with active disease from an ongoing ...
BMJ12d
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive ...
BMJ3d
POS0894 ANTI-IL-6 THERAPY EFFECT FOR REFRACTORY JOINT AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A REAL-WORLD, SINGLE CENTER EXPERIENCE
Background: Emerging evidence during the last two decades supports a pivotal role of Interleukin 6 (IL-6) in the pathogenesis of Systemic Sclerosis (SSc). Standard immunosuppressive agents are often ...
BMJ11d
Mortality and causes of death in a Swedish series of systemic sclerosis patients
OBJECTIVES To analyse survival rates and the causes of death in a systemic sclerosis (SSc) population, and to evaluate the occurrence of fatal malignant neoplasms and their possible association with ...
BMJ10d
AB0053 BERGENIN, ACTING AS AN AGONIST OF SIRT1, REDUCE SERUM URATE IN MICE THROUGH THE UPREGULATION OF ABCG2
Background: About 20% of individuals in the USA have asymptomatic hyperuricaemia [1]. However, Urate-lowering therapy in asymptomatic hyperuricaemia condition is still controversial considering the ...